Literature DB >> 19640847

Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities.

Janin Schütt1, Katrin Falley, Dietmar Richter, Hans-Jürgen Kreienkamp, Stefan Kindler.   

Abstract

Functional absence of fragile X mental retardation protein (FMRP) causes the fragile X syndrome, a hereditary form of mental retardation characterized by a change in dendritic spine morphology. The RNA-binding protein FMRP has been implicated in regulating postsynaptic protein synthesis. Here we have analyzed whether the abundance of scaffold proteins and neurotransmitter receptor subunits in postsynaptic densities (PSDs) is altered in the neocortex and hippocampus of FMRP-deficient mice. Whereas the levels of several PSD components are unchanged, concentrations of Shank1 and SAPAP scaffold proteins and various glutamate receptor subunits are altered in both adult and juvenile knock-out mice. With the exception of slightly increased hippocampal SAPAP2 mRNA levels in adult animals, altered postsynaptic protein concentrations do not correlate with similar changes in total and synaptic levels of corresponding mRNAs. Thus, loss of FMRP in neurons appears to mainly affect the translation and not the abundance of particular brain transcripts. Semi-quantitative analysis of RNA levels in FMRP immunoprecipitates showed that in the mouse brain mRNAs encoding PSD components, such as Shank1, SAPAP1-3, PSD-95, and the glutamate receptor subunits NR1 and NR2B, are associated with FMRP. Luciferase reporter assays performed in primary cortical neurons from knock-out and wild-type mice indicate that FMRP silences translation of Shank1 mRNAs via their 3'-untranslated region. Activation of metabotropic glutamate receptors relieves translational suppression. As Shank1 controls dendritic spine morphology, our data suggest that dysregulation of Shank1 synthesis may significantly contribute to the abnormal spine development and function observed in brains of fragile X syndrome patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19640847      PMCID: PMC2757949          DOI: 10.1074/jbc.M109.042663

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

Review 1.  Molecular anatomy of the postsynaptic density.

Authors:  Shigeo Okabe
Journal:  Mol Cell Neurosci       Date:  2007-01-25       Impact factor: 4.314

Review 2.  FMR1: a gene with three faces.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Biochim Biophys Acta       Date:  2009-02-21

3.  Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice.

Authors:  Brian M Wilson; Charles L Cox
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-07       Impact factor: 11.205

4.  Translational regulation of the human achaete-scute homologue-1 by fragile X mental retardation protein.

Authors:  Michael Fähling; Ralf Mrowka; Andreas Steege; Karin M Kirschner; Edgar Benko; Benjamin Förstera; Pontus B Persson; Bernd J Thiele; Jochen C Meier; Holger Scholz
Journal:  J Biol Chem       Date:  2008-12-19       Impact factor: 5.157

5.  The insulin receptor substrate of 53 kDa (IRSp53) limits hippocampal synaptic plasticity.

Authors:  Corinna Sawallisch; Kerstin Berhörster; Andrea Disanza; Sara Mantoani; Michael Kintscher; Luminita Stoenica; Alexander Dityatev; Sabrina Sieber; Stefan Kindler; Fabio Morellini; Michaela Schweizer; Tobias M Boeckers; Martin Korte; Giorgio Scita; Hans-Jürgen Kreienkamp
Journal:  J Biol Chem       Date:  2009-02-10       Impact factor: 5.157

6.  Shank1 mRNA: dendritic transport by kinesin and translational control by the 5'untranslated region.

Authors:  Katrin Falley; Janin Schütt; Peter Iglauer; Katharina Menke; Christoph Maas; Matthias Kneussel; Stefan Kindler; Fred S Wouters; Dietmar Richter; Hans-Jürgen Kreienkamp
Journal:  Traffic       Date:  2009-04-11       Impact factor: 6.215

7.  Enhanced NMDA receptor-mediated synaptic transmission, enhanced long-term potentiation, and impaired learning and memory in mice lacking IRSp53.

Authors:  Myoung-Hwan Kim; Jeonghoon Choi; Jinhee Yang; Woosuk Chung; Ji-Hyun Kim; Sang Kyoo Paik; Karam Kim; Seungnam Han; Hyejung Won; Young-Soo Bae; Suk-Hee Cho; Jinsoo Seo; Yong Chul Bae; Se-Young Choi; Eunjoon Kim
Journal:  J Neurosci       Date:  2009-02-04       Impact factor: 6.167

8.  Synapse-associated protein 102/dlgh3 couples the NMDA receptor to specific plasticity pathways and learning strategies.

Authors:  Peter C Cuthbert; Lianne E Stanford; Marcelo P Coba; James A Ainge; Ann E Fink; Patricio Opazo; Jary Y Delgado; Noboru H Komiyama; Thomas J O'Dell; Seth G N Grant
Journal:  J Neurosci       Date:  2007-03-07       Impact factor: 6.167

9.  A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability.

Authors:  Francesca Zalfa; Boris Eleuteri; Kirsten S Dickson; Valentina Mercaldo; Silvia De Rubeis; Alessandra di Penta; Elisabetta Tabolacci; Pietro Chiurazzi; Giovanni Neri; Seth G N Grant; Claudia Bagni
Journal:  Nat Neurosci       Date:  2007-04-08       Impact factor: 24.884

10.  A novel function for fragile X mental retardation protein in translational activation.

Authors:  Elias G Bechara; Marie Cecile Didiot; Mireille Melko; Laetitia Davidovic; Mounia Bensaid; Patrick Martin; Marie Castets; Philippe Pognonec; Edouard W Khandjian; Hervé Moine; Barbara Bardoni
Journal:  PLoS Biol       Date:  2009-01-20       Impact factor: 8.029

View more
  71 in total

Review 1.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

2.  Gender-specific effect of Mthfr genotype and neonatal vigabatrin interaction on synaptic proteins in mouse cortex.

Authors:  Elinor Blumkin; Tamar Levav-Rabkin; Osnat Melamed; Dalia Galron; Hava M Golan
Journal:  Neuropsychopharmacology       Date:  2011-04-13       Impact factor: 7.853

3.  Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling.

Authors:  Ravi S Muddashetty; Vijayalaxmi C Nalavadi; Christina Gross; Xiaodi Yao; Lei Xing; Oskar Laur; Stephen T Warren; Gary J Bassell
Journal:  Mol Cell       Date:  2011-06-10       Impact factor: 17.970

Review 4.  Cellular and synaptic network defects in autism.

Authors:  João Peça; Guoping Feng
Journal:  Curr Opin Neurobiol       Date:  2012-03-20       Impact factor: 6.627

5.  Fragile X mental retardation protein has a unique, evolutionarily conserved neuronal function not shared with FXR1P or FXR2P.

Authors:  R Lane Coffee; Charles R Tessier; Elvin A Woodruff; Kendal Broadie
Journal:  Dis Model Mech       Date:  2010-05-04       Impact factor: 5.758

6.  Widespread Alterations in Translation Elongation in the Brain of Juvenile Fmr1 Knockout Mice.

Authors:  Sohani Das Sharma; Jordan B Metz; Hongyu Li; Benjamin D Hobson; Nicholas Hornstein; David Sulzer; Guomei Tang; Peter A Sims
Journal:  Cell Rep       Date:  2019-03-19       Impact factor: 9.423

Review 7.  Nervous translation, do you get the message? A review of mRNPs, mRNA-protein interactions and translational control within cells of the nervous system.

Authors:  Ross Smith; Reena Jagdish Rathod; Shalini Rajkumar; Derek Kennedy
Journal:  Cell Mol Life Sci       Date:  2014-06-22       Impact factor: 9.261

8.  Environmental enrichment reveals effects of genotype on hippocampal spine morphologies in the mouse model of Fragile X Syndrome.

Authors:  Julie C Lauterborn; Matiar Jafari; Alex H Babayan; Christine M Gall
Journal:  Cereb Cortex       Date:  2013-09-17       Impact factor: 5.357

Review 9.  The translation of translational control by FMRP: therapeutic targets for FXS.

Authors:  Jennifer C Darnell; Eric Klann
Journal:  Nat Neurosci       Date:  2013-04-14       Impact factor: 24.884

10.  Signals, synapses, and synthesis: how new proteins control plasticity.

Authors:  R Suzanne Zukin; Joel D Richter; Claudia Bagni
Journal:  Front Neural Circuits       Date:  2009-10-07       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.